Cancer discovery news

The number of trains serving The London Cancer Hub’s local rail station, Belmont, is set to double thanks to £14m from the Government’s Levelling Up Fund.

Cancer cells can shrink or super-size themselves to survive drug treatment or other challenges within their environment, researchers have discovered.

The team of scientists who made a ground-breaking gene discovery which transformed the field of cancer research have been celebrated with the unveiling of two commemorative plaques in London today. The plaques pay homage to the 41 scientists who made the landmark discovery of the BRCA2 cancer gene at the ICR in 1995.

Cyclist Christine O’Connell set up the One More City campaign shortly before she was diagnosed with stage 4 breast cancer in 2018. She and her teammates are now riding to fund a PhD studentship at The Institute of Cancer Research.

Removing a single protein from cells that surround tumours can improve the sensitivity of certain cancers to immunotherapy, researchers have found.

The first UK trial to test the benefits of proton beam therapy for certain patients with breast cancer has launched in the UK. The trial will compare proton beam therapy – which can target radiotherapy beams more precisely – with standard radiotherapy for patients who are at greater risk of long-term heart problems after radiotherapy treatment.

A new type of treatment strategy targeting a protein found on the surface of the most lethal prostate cancers could hold promise against the disease.

By studying rare cases of identical twins with leukaemia, scientists have shed new light on the origins of the most common type of childhood cancer – confirming it originates in the womb but that events after birth determine whether or not clinical leukaemia develops.

The Wren Chapel at the Royal Hospital Chelsea was full of guests and famous faces on 6 December, celebrating the 20th Carols from Chelsea service in support of The Institute of Cancer Research, London.

We have picked 10 exciting scientific discoveries from the past academic year that brilliantly showcase the quality, breadth and strategic impact of our research.

Scientists have created a comprehensive tool for predicting an individual’s risk of developing prostate cancer, which they say will help ensure that those men at greatest risk will receive the appropriate testing while reducing unnecessary – and potentially invasive – testing for those at very low risk.

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial.